
|Articles|March 31, 2022
The Science Behind Using Circulating Tumor DNA for MCC
Author(s)Mary Scoviak, Managing Editor
In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5


















